RoyalMax Biotechnologies Submits for Processing and Medical Sales Licenses

November 6, 2019 – Toronto, Ontario – Matica Enterprises Inc. (MMJ – CSE) (MMJFF – OTCQB) (39N – Frankfurt) (“Matica” or the “Company”)  is pleased to announce that RoyalMax Biotechnology Canada Inc. (“RoyalMax”) has submitted to Health Canada applications for amendments to the current license to add a Standard Processing License and a Sales for Medical Purposes License. Upon receipt of these licences RoyalMax will begin sales of cannabis produced at its facility in Dorval, Quebec.

Mr. Charn Deol, Matica CFO states that, “It will be exciting to show sales and revenue coming from Dorval. The Dorval facility has been growing cannabis for several months now and shareholders expect to see the company generating sales.”

Matica is currently in the permitting phase of its 200,000 square foot greenhouse project in Hemmingford, Quebec. The site is prepared for construction to begin. Permits are expected shortly, and construction will begin immediately thereafter.

Cannabis 2.0
Matica has been gearing up for Cannabis 2.0. With the amended regulations in Canada, edibles containing cannabis and cannabis concentrates became legal on October 17, 2019 as have topicals.  Working with Yunify Natural Technologies and through its acquisition of Trichome Treats, Matica and RoyalMax intend on introducing  new products and are creating new opportunities..

About Matica
Matica is a multi-faceted, innovative company in the Quebec cannabis space. RoyalMax Biotechnology Canada Inc. has been granted a standard cultivation licence by Health Canada for the production facility in Dorval, Quebec. Matica intends to build 1,000,000 square feet of greenhouses, in 200,000 square foot increments, on a 181 acre property in the township of Hemmingford, south of Montreal. Matica has entered into an agreement with Yunify Natural Technologies, a Quebec based health and personal care research and innovation company to develop proprietary products for Matica and RoyalMax.


For more information on Matica Enterprises please visit the website at:

On behalf of the Board of Directors


Boris Ziger

Boris Ziger, CEO & Chairman


The Company’s public filings are available for review at and


For further information, please contact Boris Ziger, at:

Telephone: 416-304-9935


Website: ,


Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at

This news release contains statements about the Company’s information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties.  Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.